Regeneron secures priority review for Eylea's use in infant retinopathy

Three years ago, the FDA cleared Regeneron’s Eylea for use against diabetic retinopathy, a condition that strikes more than a third of diabetics and can cause blindness.

Now the company is working to extend Eylea’s reach to infants with another version of the disorder—retinopathy of prematurity (ROP)—which often happens to babies born less than 31 weeks into pregnancy or weighing less than 3.3 pounds.